PCSA

Processa Pharmaceuticals, Inc. Common

1.87

USD

-0.08

-4.10%

Nov 10, 15:59 UTC -5

Closed

After-Market

1.90

+0.02

+1.34%

Processa Pharmaceuticals, Inc. Common (PCSA) Earnings

PCSA Earnings Reports

Positive Surprise Ratio

PCSA beat 7 of 21 last estimates.

33%

Next Report

Date of Next Report

Mar 16, 2027

Estimate for Q4 26 (Revenue/ EPS)

-$0.76

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

-70.43%

Processa Pharmaceuticals, Inc. Common earnings per share and revenue

On Nov 06, 2026, PCSA reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -1.02 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.76 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Definium Therapeutics, Inc. Common Shares

Report Date

Nov 09, 2026 For Q3 26

Estimate

-$0.56

Actual

-$0.46

Surprise

+19.06%

Ocular Therapeutix, Inc.

Report Date

Nov 09, 2026 For Q3 26

Estimate

-$0.36

Actual

-$0.42

Surprise

-13.54%

Harrow, Inc. Common Stock

Report Date

Nov 09, 2026 For Q3 26

Estimate

$0.22

Actual

$0.12

Surprise

-45.92%

SIGA Technologies Inc.

Report Date

Nov 09, 2026 For Q3 26

Estimate

Actual

-$0.04

Surprise

Protara Therapeutics, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.35

Surprise

+6.17%

Minerva Neurosciences, Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.12

Actual

$1.94

Surprise

+1,629.97%

Tonix Pharmaceuticals Holding Corp.

Report Date

Nov 09, 2026 For Q3 26

Estimate

-$2.40

Actual

-$2.89

Surprise

-20.23%

Cumberland Pharmaceuticals Inc

Report Date

Nov 10, 2026 For Q3 26

Estimate

Actual

-$0.07

Surprise

PMV Pharmaceuticals, Inc

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.34

Actual

-$0.28

Surprise

+15.55%

Corbus Pharmaceuticals Holdings, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$1.23

Actual

-$1.81

Surprise

-46.07%

FAQ

What were Processa Pharmaceuticals, Inc. Common's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Processa Pharmaceuticals, Inc. Common reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to Processa Pharmaceuticals, Inc. Common's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Processa Pharmaceuticals, Inc. Common expected to report next?

The next earning report is scheduled for Mar 16, 2027.

What are the forecasts for Processa Pharmaceuticals, Inc. Common's next earnings report?

Based on -- analysts, Processa Pharmaceuticals, Inc. Common is expected to report EPS of -$0.76 and revenue of -- for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.